Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

More than 100 marchers took to Capitol Hill on Wednesday, carrying a coffin to the FDA in a symbolic protest highlighting ...

Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, ...

Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

Stroke treatment hardware developer Imperative Care has posted a $100 million funding round to support its commercial growth ...

R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and ...

After increasing its stake in the infectious disease testmaker last year, Altai Capital Management is now pushing OraSure ...

Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX Therapeutics six years after the two companies ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

One of the world’s largest hearing aid retailers plans to bring a top manufacturer under its roof in a major acquisition that ...